Chronic ischemia increases prostatic smooth muscle contraction in the rabbit

Journal of Urology

Volumn 170, Issue 2 I, 2003, Pages 659-663

  Azadzoi, Kazem M ^a,c   Babayan, Richard K ^a   Kozlowski, Robert ^b   Siroky, Mike B ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Neurology Research 151   (United States)

Author keywords

Doxazosin; Ischemia; Muscle contraction; Prostate; Rabbits

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ARGININE; CYCLIC GMP; DOXAZOSIN; GUANYLATE CYCLASE INHIBITOR; METHYLENE BLUE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM INJURY; ENZYME IMMUNOASSAY; ILIAC ARTERY; ISCHEMIA; MALE; MICTURITION; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE CONTRACTION;

EID: 0038507051     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000064923.29954.7e     Document Type: Article

References (20)

1. McConnell, J. D.: Epidemiology, etiology, pathophysiology and diagnosis of benign prostatic hyperplasia. In: Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., p. 1429, 1998
2. Elliott, H. L., Meredith, P. A., Sumner, D. J., McLean, K. and Reid, J. L.: A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol, 13: 699, 1982
3. Lepor, H. and Machi, G.: Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology, 42: 36, 1993
4. Azadzoi, K. M., Tarcan, T., Siroky, M. B. and Krane, R. J.: Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol, 161: 1626, 1999
5. Coker, C., Sherwood, R. A., Crayford, T., Saadeh, F., Mulvin, D., Brakenbury, E. et al: Ischemic damage to the prostate during cardiac surgery: a clinical model. Prostate, 32: 85, 1997
6. Koller-Strametz, J., Fritzer, M., Gwechenberger, M., Geppert, A., Heinz, G., Haumer, M. et al: Elevation of prostate-specific markers after cardiopulmonary resuscitation. Circulation, 102: 290, 2000
7. Kozlowski, R., Kershen, R. T., Siroky, M. B., Krane, R. J. and Azadzoi, K. M.: Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol, 165: 1019, 2001
8. Shabsigh, A., Ghafar, M. A., de la Taille, A., Burchardt, M., Kaplan, S.A., Anastasiadis, A. G. et al: Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem, 81: 437, 2001
9. Lekas, E., Engstrand, C., Bergh, A. and Damber, J. E.: Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res, 27: 174, 1999
10. Madersbacher, S., Klingler, H. C., Schatzl, G., Stulnig, T., Schmidbauer, C. P. and Marberger, M.: Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol, 156: 1662, 1996
11. Bercovich, E., Barabino, G. and Pirozzi-Farina, F.: Age related fibrosis is the main factor of urinary symptoms in benign prostate hypertrophy BPH patients. J Urol, suppl., 161: 235, abstract 903, 1999
12. Bosh, J. L. H. R., Kranse, R., van Mastright, R. and Schröder, F. H.: Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol, 153: 689, 1995
13. Shapiro, E., Hartanto, V. and Lepor, H.: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol, 147: 1167, 1992
14. Azadzoi, K. M., Tarcan, T., Kozlowski, R., Krane, R. J. and Siroky, M. B.: Overactivity and structural changes in the chronically ischemic bladder. J Urol, 162: 1768, 1999
15. Dinlenc, C. Z., Liatsikos, E. N. and Smith, A. D.: Ureteral ischemia model: an explanation of ureteral dysfunction after chronic obstruction. J Endourol, 16: 47, 2002
16. Ignarro, L. J. and Kadowitz, P. J.: The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol, 25: 171, 1985
17. Jeremy, J. Y., Ballard, S. A., Naylor, A. M., Miller, M. A. and Angelini, G. D.: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol, 79: 958, 1997
18. Adolfsson, P. I., Ahlstrand, C., Varenhorst, E. and Svensson, S. P.: Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate, 51: 50, 2002
19. Truss, M. C., Stief, C. G., Uckert S, Becker, A. J., Wefer, J., Schultheiss, D. et al: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol, 19: 344, 2001
20. Diokno, A. C., Brock, B. M., Herzog, A. R. and Bromberg, J.: Medical correlates of urinary incontinence in the elderly. Urology, 36: 129, 1990